Trocoxil

Quick links to important sections

Trocoxil

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trocoxil

Quick Facts

Property Description
Active Ingredient Mavacoxib
Form Chewable tablets
Pharmacological Class Selective COX-2 Inhibitor (Coxib)
General Purpose Anti-inflammatory and pain relief
Origin Synthetic

What is Trocoxil?

Trocoxil is a prescription-only medicine authorized as a veterinary drug developed exclusively for canine patients (dogs). It is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and functions as a selective modulator of the inflammatory process. The medication is not intended for human use.


Trocoxil's Composition and Physical Form

The core component of Trocoxil is its single active ingredient, the synthetic chemical compound, Mavacoxib. Mavacoxib belongs to the Coxib class of NSAIDs, distinguishing itself as a selective Cyclooxygenase-2 (COX-2) inhibitor. This classification ensures the substance primarily targets the COX-2 enzyme, which is central to generating pain and swelling signals in the body. The formulation is administered via oral administration and supplied in the form of chewable tablets.


What is the General Purpose of Trocoxil?

The overall therapeutic objective of Trocoxil is to provide sustained anti-inflammatory and analgesic (pain-relieving) action. The differentiating feature of Mavacoxib is its long-acting profile, which is achieved through its inherently slow elimination rate from the target species. By acting as a selective COX-2 inhibitor, the medication helps to mitigate the chemical mediators responsible for generating chronic discomfort in dogs, offering a consistent approach to long-term management of inflammatory conditions.

What side effects are possible with Trocoxil?

Possible Side Effects and Safety Information

The safety profile for Trocoxil (Mavacoxib) is primarily structured around the risks associated with the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, focused on the gastrointestinal and renal systems, as classified by regulatory authorities.


Officially Documented Adverse Reactions

Adverse reactions are classified by frequency based on official regulatory data:

Classification System-Organ Class Examples of Effects
Common Gastrointestinal Disorders Vomiting, Diarrhoea
Uncommon Gastrointestinal, Renal, General Disorders Apathy, Appetite loss, Bloody diarrhoea, Melaena, Impaired renal function
Rare Gastrointestinal Disorders Gastric ulcer, Small intestine ulcer

Serious Reactions and Safety Constraints

The most significant documented risks involve severe gastrointestinal ulceration and renal dysfunction, which, in rare cases, have been associated with fatal outcomes. The medicine's extended presence in the body means that adverse reactions may occur and persist for up to one to two months following the final administration.

Official labeling mandates several constraints and contraindications. Trocoxil should not be used in individuals with pre-existing conditions such as gastro-intestinal disorders (ulceration or bleeding), haemorrhagic disorder, impaired renal function, impaired hepatic function, or cardiac insufficiency.

Restrictions also apply to specific populations: the medicine is contraindicated in young individuals (under 12 months of age or under 5 kg body weight), as well as in pregnant, breeding, or lactating individuals. Additionally, use is restricted in any dehydrated, hypovolaemic, or hypotensive status.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Trocoxil (mavacoxib), a non-steroidal anti-inflammatory drug (NSAID), is primarily associated with toxic effects on the gastrointestinal system and renal (kidney) function. Regulatory documents indicate that the major clinical manifestations observed in overdose scenarios include gastrointestinal ulceration, vomiting, and increases in clinical chemistry parameters that reflect kidney impairment. In rare cases, these adverse reactions have been reported to be fatal.

Since Trocoxil has a prolonged pharmacological effect, the possibility of sustained adverse effects must be considered in any overdose situation.


Accidental Ingestion and Emergency Actions

If accidental self-ingestion by a human occurs, immediate medical advice must be sought by contacting emergency services or a poison control center, and the package labeling should be shown to the medical professional. Ingestion may be especially harmful to children, potentially leading to prolonged gastrointestinal disorders.

If an overdose is suspected, there is no specific antidote for mavacoxib. Management involves stopping any further administration of the drug and providing general supportive therapy that is standard for NSAID overdose. Particular attention is required to maintain the patient's hemodynamic status (blood circulation and pressure) throughout treatment. Individuals with known hypersensitivity to NSAIDs should avoid all contact with the product.

Therapeutic Uses of Trocoxil

What Trocoxil Treats: Main Uses and Benefits

Trocoxil is commonly used for managing pain and inflammation associated with degenerative joint disease, particularly in conditions where longer-term symptomatic support may be appropriate.

The medicine is relevant for patients experiencing conditions marked by chronic, ongoing joint discomfort. The medicine is generally applied in addressing symptom clusters that include pain, inflammation, stiffness, and reduced physical movement. It may be part of symptomatic management for patients diagnosed with osteoarthritis and degenerative joint disease, and it may be considered for senior individuals or those with a high predisposition to joint problems.

“The treatment supports the patient during difficult episodes by helping to ease distress and may contribute to general well-being during symptomatic phases.”

By helping to moderate the intensity of these painful manifestations, the treatment contributes to supportive symptomatic relief. This assists with maintaining functional stability when symptoms interfere with routine activities, contributing to easing the overall symptom load.


Quick Fact: Relief for Chronic Joint Discomfort

Trocoxil is commonly used to help manage the symptoms related to long-term musculoskeletal issues, supporting functional stability during phases when discomfort becomes more noticeable.

Regulatory References

  1. Summary of Product Characteristics (SPC) for Trocoxil

Eligibility and Restrictions for Use

Who can and cannot use Trocoxil?

Trocoxil (Mavacoxib) is a prescription-only veterinary medicine authorized exclusively for use in canine patients (dogs). Official regulatory eligibility is strictly based on specific patient criteria.

Populations Approved for Use

The medicine is approved only for dogs that are 12 months of age or older and have a minimum body weight of 5 kilograms.

Contraindications (Who Must Not Use Trocoxil)

Trocoxil is absolutely contraindicated in numerous patient groups. It must not be used in dogs with:

  • Impaired renal or hepatic function (kidney or liver impairment).
  • Cardiac insufficiency (heart failure).
  • Pre-existing gastro-intestinal disorders (including ulceration and bleeding).
  • A known haemorrhagic disorder (bleeding tendency).
  • Known hypersensitivity to Mavacoxib, its excipients, or to sulphonamides.
  • Pregnant, breeding, or lactating animals, as safety has not been established.

Use is also officially advised to be avoided in any animal that is currently dehydrated, hypovolaemic, or hypotensive. Concurrent treatment with other NSAIDs or glucocorticoids is also restricted, defining a boundary for treatment eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Mavacoxib (Trocoxil) identifies specific combinations and administration constraints related to its pharmacological action and prolonged presence in the system. All interaction constraints stem from officially documented patterns.

Restricted Combinations and Required Monitoring

Classification Interacting Agents Constraint
Contraindicated Glucocorticoids Must not be used simultaneously.
Contraindicated Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Must not be used simultaneously.
Avoidance Mandated Potentially Nephrotoxic Medicinal Products Concurrent administration must be avoided due to the potential for increased renal toxicity.
Use with Caution Anticoagulants Requires careful monitoring due to potential for competition for plasma protein binding.

Timing and Population Restrictions

The long elimination half-life of Mavacoxib necessitates strict timing constraints. A mandatory treatment-free period of at least 24 hours is required when substituting a previous NSAID with Trocoxil. Conversely, a prolonged treatment-free period of at least ONE MONTH must be ensured after the last dose before administering another NSAID or Glucocorticoid. This constraint applies throughout the product's extended effect period.

The risk of excessive accumulation due to reduced clearance makes treatment contraindicated in patients with hepatic disorders. Furthermore, use should be avoided in dehydrated, hypovolaemic, or hypotensive animals, as their systemic state may increase the risk of potential renal toxicity when other agents are involved.

Mechanism of Action

Selective Inhibition of the COX-2 Enzyme

The molecule, Mavacoxib, functions as a highly specific inhibitor by preferentially binding to the active site of the Cyclooxygenase-2 ( COX-2) enzyme, largely sparing the constitutive COX-1 enzyme. This targeted action interrupts the early molecular step in the inflammatory cascade, preventing the enzyme from converting Arachidonic Acid into pro-inflammatory signals.

Modulation of Inflammatory Mediator Synthesis

By blocking COX-2, Mavacoxib substantially reduces the localized synthesis of key inflammatory prostaglandins (such as PGE2) at the site of tissue irritation. The physiological consequence of this is a reduction in the chemical messengers responsible for vasodilation and increased vascular permeability, which results in the modulation of inflammatory mediator activity.

Decoupling of Peripheral Pain Signaling

The reduction of prostaglandins prevents the hyper-sensitization of peripheral nociceptors (pain-sensing nerve endings). This physiological effect raises the threshold required for these nerves to transmit pain signals, thereby resulting in a modulation of nociceptive signaling and contributing to the modulation of peripheral pathway activity.

Dosage and Administration Information

How Trocoxil is Used


Administration Route and Dose

Trocoxil is intended for oral use and is supplied as chewable tablets. The standard dose is established at 2 mg of mavacoxib per kilogram of body weight. This dose is determined based on the dog's weight at the time of administration. The medication is for use in dogs aged 12 months or older and weighing at least 5 kg.


Official Dosing Schedule

Usage follows a specific long-interval schedule and is not a daily medication. The treatment cycle begins with the first dose, followed by a second dose administered 14 days later. After this initial period, the maintenance dosing interval is one month.


Administration Requirements and Constraints

The tablet must be given immediately before or during the dog’s main meal. Care must be taken to ensure the tablet is fully ingested. The course of treatment is limited and should not exceed seven consecutive doses.

Specific washout periods are required when transitioning between Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). When switching to Trocoxil from a different NSAID, a treatment-free period of at least 24 hours is required before the first dose. Due to the prolonged activity of mavacoxib, a treatment-free period of at least one month must be observed after the final Trocoxil dose before administering any other NSAID.

Recent Clinical Evidence

Trocoxil: Recent Clinical Evidence

Evidence for use in Degenerative Joint Disease (Osteoarthritis)

Trocoxil (Mavacoxib) was evaluated in clinical trials for its approved use in dogs presenting with conditions characterized by fluctuating or episodic manifestations of joint discomfort. The core evidence consists of Randomized Controlled Trials (RCTs) set up to research exploring short-term symptom changes in dogs diagnosed with naturally occurring Osteoarthritis.

Studies examined changes reported by owners and veterinarians using validated scoring tools to assess lameness, stiffness, and clinical discomfort indicators. Trials also monitored objective functional measurements like Peak Vertical Force (PVF), which assesses weight-bearing capacity in a limb.

Findings describe patterns observed over short evaluation periods, highlighting changes measured for outcomes reflecting daily functioning or activity level. The data related to PVF measurements were compared to baseline. Research provides context but not individual predictions.


Comparator Trials and Study Outcome Measurement

Research examined how outcomes were measured when comparing the drug against a placebo and other established, active Non-Steroidal Anti-Inflammatory Drug (NSAID) comparators. The primary research goal was studied for assessing whether outcomes related to physical discomfort measured in the Mavacoxib group followed similar patterns observed in the studies of the active comparator treatments. Outcomes were compared between the drug group and the placebo group using objective gait analysis (PVF).


Long-Term Studies and Observation Periods

The clinical development program included follow-up durations ranging up to 134 days (about 4.5 months). The maximum continuous treatment period officially cited by the regulator is 6.5 months. Long-term effects are not fully established, and certainty remains low regarding the study coverage of continuous use over several years.


Evidence for Specific Patient Groups and Key Limitations

The main clinical trials specifically excluded dogs younger than 12 months of age or those weighing less than 5 kg; therefore, data for certain groups remain insufficient. Research also describes patterns of inter-individual variability in the drug’s elimination profile, where a small subgroup of animals studied took significantly longer to clear the drug from the body. This highlights a variation in individual responses.

Key Studies & References

  1. Trocoxil, INN-Mavacoxib (Summary of Product Characteristics and Public Assessment Report)
  2. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Trocoxil (FAQ)


Q: How quickly should I expect to see an effect after my dog starts Trocoxil?

The official product information indicates that Trocoxil has a characteristic long-lasting presence in the body. Because of this extended persistence, the anti-inflammatory and pain-relieving effects are described as persisting for up to one to two months following the second dose and subsequent maintenance doses.


Q: What are the signs of an allergic reaction to Trocoxil?

While regulatory information lists known hypersensitivity (allergic reaction) to Trocoxil or its components as a reason the drug must not be used, the specific signs of an allergic reaction are not detailed in the product's adverse reaction tables. Official guidance notes that general supportive therapy appropriate for NSAID reactions may be used if an adverse reaction occurs.


Q: Is Trocoxil known to interact with heartworm preventatives?

Official regulatory documents state that no formal drug interaction studies have been performed with Trocoxil. The main interaction constraints focus on avoiding concurrent use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or steroids. Concurrent use with an anticoagulant (a drug that affects blood clotting) is a situation where careful monitoring is advised.


Q: Why does Trocoxil stay in the system longer than other NSAIDs?

Trocoxil (Mavacoxib) belongs to the Coxib class of NSAIDs, but its distinguishing feature is its extended plasma half-life. This means the drug is eliminated from the body at a very slow rate, which is why it can remain active in the system for a prolonged period, sometimes exceeding 80 days.


Q: Does Trocoxil help with conditions other than osteoarthritis?

Official documents specify that the medicine is indicated solely for the treatment of pain and inflammation associated with degenerative joint disease (osteoarthritis) in dogs. Its use is authorized only in situations where long-term management of this specific condition is needed.


Q: What should I monitor for when my dog is on Trocoxil?

Regulatory guidance suggests that a clinical examination and appropriate laboratory tests are recommended both before and during treatment. These tests are recommended to help monitor key health indicators, such as haematology (blood components) and clinical chemistry, while the dog is on the medication.


Q: If Trocoxil works, why can't it be used every day?

Trocoxil cannot be used daily because of its extended plasma half-life and uniquely slow elimination rate from the body. If administered more frequently than the prescribed schedule, the potential for excessive accumulation exists due to its slow elimination rate.


Q: Can my dog take Trocoxil if they are on antibiotics?

No formal drug interaction studies have been conducted between Trocoxil and antibiotics. Regulatory information notes that NSAIDs are highly bound to plasma proteins, and caution is necessary because Trocoxil could compete for binding sites with other highly protein-bound substances that are administered concurrently.


Q: What happens if a dog accidentally takes too much Trocoxil?

In the event of an adverse reaction, the official guidance is to stop administering any further tablets. Official guidance indicates that general supportive therapy, such as that typically applied for NSAID overexposure, may be necessary.


Q: Why are there different tablet sizes of Trocoxil?

Trocoxil chewable tablets are supplied in various strengths (such as 6 mg, 20 mg, 75 mg). This is intended to allow for dosing as close as possible to the authorized amount, as the authorized dose is precisely calculated based on the dog's individual body weight.


Q: Can Trocoxil be given alongside tramadol or gabapentin?

Official regulatory documents indicate that no specific interaction studies have been performed with drugs like tramadol or gabapentin. Caution is generally advised when combining Trocoxil with any substance that is highly protein-bound, as competition for binding sites could potentially alter how both medications work.


Q: What is the difference between Trocoxil and meloxicam?

Trocoxil (Mavacoxib) and meloxicam are both Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Trocoxil is primarily differentiated by its prolonged elimination half-life and the resulting unique, long-interval dosing schedule.


Q: Are blood tests required before starting Trocoxil treatment?

Yes. According to the special precautions for use, appropriate laboratory tests are recommended before treatment begins. These tests are recommended to help monitor key health parameters, specifically checking haematology and clinical chemistry, to determine eligibility for the medication.


Q: What regulatory bodies have approved Trocoxil?

Trocoxil was authorized for the European Union market following an assessment by the European Medicines Agency (EMA). The final approval, which makes it available as a veterinary medicine, was issued by the European Commission.


Q: Why is Trocoxil mentioned with a 'half-life' in medical documents?

The term half-life describes the time required for the concentration of the drug in the blood plasma to drop by half. For Trocoxil, medical documents use the term 'extended plasma half-life' to explain its long duration of effect, which can be over 80 days. This slow clearance is the reason the medication is given on a long-interval schedule.


Q: How is Trocoxil different from typical human NSAIDs?

Trocoxil is unique in that it is developed and authorized exclusively as a veterinary drug for dogs. A significant differentiating factor is its pharmacological profile, which involves a substantially extended plasma half-life, necessitating a unique, long-interval dosing schedule rather than daily use.

How should Trocoxil be stored and disposed of?

How to Store and Dispose of Trocoxil?

The storage and disposal of Trocoxil (mavacoxib) chewable tablets are strictly defined by regulatory requirements to ensure product stability and prevent harm.


Storage Requirements

Trocoxil must be stored either below 30 C or requires no special temperature conditions, depending on the regional formulation. The tablets have a shelf life of 3 years and must be kept in the original package with the blister remaining in the outer carton. To protect children from accidental ingestion, the product must be kept out of the sight and reach of children and administered immediately after removal from the blister.


Disposal Instructions

Unused or expired Trocoxil should not be disposed of via wastewater or household waste. All remaining material must be handled as pharmaceutical waste and disposed of according to local requirements, often requiring classification as toxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trocoxil found in:

A-Z Index: